Review reports better sleep measures but modest effects on depressive symptoms
Studies of daridorexant, lemborexant, and suvorexant reported sleep improvements, including in people with depression, while long-term effectiveness and safety remain uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported improvements in the time taken to fall asleep, wakefulness after sleep began, and total sleep time with dual orexin receptor antagonists. Effects on depressive symptoms were modest. This suggests a more consistent sleep-related signal, but the abstract cannot establish lasting benefits or how well these medicines address depression itself.
Most studies were short, and participant groups varied substantially. The abstract supplies no comparative effect sizes or adverse-event rates, limiting judgments about the magnitude of benefit and longer-term safety.
What the review examined
Researchers examined sleep outcomes, depressive symptoms, and safety across studies of these medicines. Because the included populations covered insomnia, major depression, and healthy controls, the evidence does not come exclusively from people with depression.
How to read the safety findings
Most reported adverse events were mild or moderate, and the authors described safety profiles as generally favorable. That summary does not establish long-term safety, which the review identifies as a question for further research.
The original publication
Efficacy and safety profiles of FDA-approved dual orexin receptor antagonists in depression: A systematic review of pre-clinical and clinical studies.
Vasudeva S, Wong S, Le GH et al.
J Psychiatr Res · 2025
- PubMed ID
- 41109037
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.